Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three ...

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to soar 35% over the next 12 months.

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

All participants also received standard care for MASH. Participants got two liver biopsies to help evaluate the effects of semaglutide. About 56% of participants had type 2 diabetes, and about 73% ...